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Introduction: The Personal Experience Screening Questionnaire (PESQ) is an instru-
ment devised for assessing the magnitude of drug misuse among adolescents. How-
ever, its psychometric properties have not been evaluated in adolescent samples outside 
the United States. 
Objective: To assess the internal reliability and validity of the Brazilian version of 
the PESQ. 
Method: A cross-sectional study was carried out with 84 adolescents from a clinical 
sample and a community-based sample. All of them answered the PESQ. 
Results: Among adolescents from the community, the PESQ problem severity index, 
which can vary from 18 to 72, was 26.48±9.28, whereas the clinical sample scored 
42.89±10.02 (p<0.001). Cronbach’s alpha was 0.91. Factor analysis resulted in a 
four-factor solution. Furthermore, both samples also had different mean scores for 
the other distinct content areas measured by the instrument. 
Conclusion: Evidence to support the reliability and validity of the Brazilian version 
of the Personal Experience Questionnaire was found.
Keywords: drugs, screening, scales, validation, reliability.
introduction
Subjectivism involved in psychiatric diagnosis and the lack 
of biological markers for mental disorders7 can become 
an important drawback to their identification. This is 
especially true when it comes to addiction, as the border-
lines between use, abuse, and dependence are not clear.10 
In order to minimize diagnostic difficulties, symptom-
based screening scales can be particularly useful.12 A favor-
able screening instrument should present good cost-ben-
efit relationship, be accurate, and consist of a small 
number of items, in order to be efficient.12 Once the at-risk 
individuals are identified by a screening tool, the subse-
quent step is a psychiatric interview.2,9,11 In this second 
stage, physicians and researchers can obtain a thorough 
comprehensive diagnosis. Assessment instruments must 
be developed or adapted to different cultural circumstanc-
es. This means that assessment measures developed for 
specific cultural environments must go under a cross-
cultural validation before its use for different populations.16 
In Brazil, national household surveys including those 
15 years of age and older reveal a consistent increase of drug 
consumption.3,4 In the First Household Survey,4 19.4% of 
surveyed Brazilians reported they have already used any 
illicit drugs; this number was of 22.8% in the Second House-
hold Survey.3 Lifetime use of marijuana totaled 6.9% in 
2001 and increased to 8.8% in 2005. The same was observed 
for inhalants (5.8 and 6.1%, respectively) and for cocaine 
(2.3 and 2.9%). In 2005, the prevalence rates of substance 
dependence disorder for illicit drugs were as follows: mar-
ijuana (1.2%), benzodiazepines without medical prescription 
(0.5%), inhalants (0.2%), and stimulants (0.2%). Alcohol 
dependence was present among 11.2% of the population 
in 2001 and among 12.3% in 2005. The World Drug Reports 
of 2012 and of 201321,22 add some relevant data. In 2012, 
while South America presented a decline in cocaine con-
sumption, Brazil increased its demand for the drug. Also, 
the 2013 Report states that Brazil has contributed with 
some new psychoactive substances, such as krokodil or 
bath salts, one of the main concerns of United Nations 
Office on Drugs and Crime (UNODC) in 2013. 
Concerning substance abuse or dependence among 
adolescents, there are a few Brazilian studies. Frequent 
drinking (at least once a week in the past month) occurs 
in 9.1% of the Brazilian adolescent population (14 to 17 
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years old), and binge drinking in 52.9% of the boys and 
in 37.6% of the girls.15 A National Survey conducted in 
Brazil found that 2.8% of adolescents (14 to 19 years old) 
had past-year use of at least one illicit drug.13 According 
to this study, the most used illicit substances were mari-
juana (1.6%), solvents (1.1%), and crack/cocaine (0.5%).
The clinical field definitely warrants the need for a 
screening instrument capable of fast and efficient identi-
fication of adolescents likely to have a substance-related 
problem. A recent systematic review identified only two 
instruments validated for screening of problems related to 
substance use among Brazilian adolescents,17 the Drug Use 
Screening Inventory (DUSI) and the Teen-Addiction Sever-
ity Index (T-ASI). Both instruments are extensive (the DUSI 
has 149 questions and the T-ASI has 153 questions) and 
take too much time to be completed. A shorter version of 
the DUSI (DUSI-R) had its psychometric properties stud-
ied among Brazilian adolescents, with good results.8 How-
ever, the DUSI-R consists of 149-items and, thus, falls short 
of being an ideal screening tool. It is important that other 
well-studied instruments are available in the Brazilian 
cultural context, in order to provide clinicians and research-
es with a broader range of questionnaires. 
The aim of this study was to validate the Brazilian 
version of a promising screening measure, the Personal 
Experience Screening Questionnaire (PESQ).23 
Method
Sample
The clinical sample involved all 41 adolescents admitted 
for treatment at the Addiction Unit (PROAD – Programa 
de Orientação e Atendimento a Dependentes, in Portu-
guese) of the Department of Psychiatric at the Federal 
University of São Paulo (Unifesp), Brazil, during 12 months. 
All of them were evaluated by a trained psychiatrist and 
by a psychologist, separately, and both confirmed the di-
agnosis of drug or alcohol dependence using a semi-struc-
tured interview based on DSM-IV-TR dependence criteria.1
The comparison non-clinical group consisted of youths 
from a high school in São Paulo, Brazil. Forty-five adoles-
cents were randomly drawn from a 120-adolescent sample. 
If a selected adolescent presented a lower age than 15 or 
higher than 18 years old, he/she was not included and 
another one was selected. The same age criterion was used 
in the clinical sample. All of them were evaluated by a 
trained psychiatrist and by a trained psychologist sepa-
rately in order to assure that they had no substance use-
related disorder. Two out of 45 were excluded in this phase, 
due to a diagnosis of alcohol dependence. Psychiatric 
comorbidities were not considered as an exclusion criteria. 
Treatment was offered for both of them and their parents. 
The two groups that formed the final sample had the 
same average age (16.6 years); however, there were more 
boys in the treatment group (75 vs. 53%) in keeping with 
findings from many studies documenting a higher preva-
lence of substance abuse among boys. As expected, a 
lower proportion of participants in the clinical sample 
were living with their parents compared to the comparison 
group (57 vs. 97%). More details are provided in Table 1. 
Instrument
Both groups were administered the Brazilian version of the 
PESQ. The PESQ is a self-administered screening question-
naire developed as part of a multi-assessment battery.23 
The instrument is formatted to have two (yes/no), three 
(never/once or twice/more than once or twice) or four 








Male 53.5 75.6 0.03
Female 46.5 24.4
Age ± SD 16.65±1.00 16.61±1.20 >0.05
Living with parents (%)
Living together – Good relationship 55.8 36.6 >0.05
Living together – Bad relationship 11.6 14.6
Divorced parents 30.2 39.0
Parents deceased 2.3 9.7
School lag (%) 0 42.9 <0.001
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(never/once or twice/sometimes/often) response options. 
The alcohol or drug use frequency items were formatted 
using a 7-point scale (1 = never; 7 = 40 times or more).23,24,26 
The 40-item PESQ questionnaire consists of five areas:
i. Drug use problem severity scale (18 items: questions 
1 to 8; 10 to 14; and 16 to 20) – aims to provide a glo-
bal measure of drug or alcohol use severity. This in-
dex provides a global measure of problem severity by 
reflecting the extent to which the individual is psycho-
logically and behaviorally involved with drugs. Sco-
ring of index consists of a simple no-weighted sum 
of the 18 items, with deviance associated by a high 
score. Scale scores range from 18 (“never” response 
to all items) to 72 (“often” response to all items); a 
nonuser would logically score 18.
ii. Efensiveness (five items: questions 22, 24, 26, 29, and 
31) – based on the Marlowe-Crowne Social Desirabi-
lity Scale,5 this set of items measures faking-good res-
ponse tendencies. It identifies teenagers with a ten-
dency to minimize or deny problems. The responses 
given usually reflect “social desirability.” On questions 
24, 26, and 31, a positive answer adds one point and a 
negative one adds two points to the score, whereas on 
questions 22 and 29 scoring is similar but reversed.
iii. Infrequency (three items: questions 9, 15, and 21) – a 
high score on this subscale is associated with faking 
bad, as it inquires about unlikely drug use behavior.
iv. Psychological indicators (eight items: questions 23, 
25, 27, 28, 30, 32, 33, and 34) – covers personal or en-
vironmental problems associated with adolescent 
drug or alcohol use. The presence of at least one po-
sitive answer for the questions above indicates the 
existence of a significant psychological stressor. 
v. Drug use history (six items: questions 35 to 40) – sum-
marizes frequency of alcohol and illicit drug use in 
the past year. 
It is not a public domain instrument and it requires a fourth 
grade reading level by the respondent. Ten minutes are 
necessary to complete all questions. The characteristics of 
the scale result in a fast and efficient instrument for drug 
use screening and for referral for a diagnostic evaluation. 
Even though its use on epidemiological researches is still 
limited, it is recommended as a standard part of clinical 
evaluation of adolescents.14 Norms for non-clinical, juvenile 
offender and drug-abusing populations are available.26 
The paper and pencil format of the PESQ was trans-
lated into Brazilian Portuguese. The translation was 
conducted using a two-step procedure. A bilingual psy-
chiatrist first translated the items from English to Bra-
zilian Portuguese followed by back translation into 
English conducted by a linguist. Discrepancies between 
the two versions were resolved during discussion by 
modifying word selection.
PESQ was administered to the clinical sample as part 
of the intake assessment upon treatment admission. The 
non-clinical sample data were gathered by a trained team 
of field researchers. Anonymous standardized paper-and-
pencil questionnaire was used. Interviews were conduct-
ed in the school, without a teacher or school member 
present in the classroom. Research objectives, anonymity, 
confidentiality, and volunteering were explained to all 
adolescents by the research team. On average, students 
took 10 minutes to complete the questionnaire.  
The DUSI was used as an instrument of comparison. 
It is a validated instrument for screening of drug use 
among adolescents. The characteristics of the scale results 
in a fast and efficient self-administered questionnaire for 
drug use screening, also useful for planning treatment 
and monitoring outcomes. 
Statistical analysis
Collected data were analyzed through the software pack-
age SPSS 20.0. Comparisons were held through chi-square 
and t-test. The variables were tested in order to verify its 
normal distribution (skewness and kurtosis) and Pearson’s 
coefficient was used in order to establish correlations. 
Internal reliability consistency was evaluated using Cron-
bach’s alpha. A level of significance of 5% was considered. 
Factor analysis was conducted with 18-item PESQ 
Scale (Problem Severity Index). This was followed by prin-
cipal components extraction with Varimax and Oblimin 
rotation. We used a) a minimum eingenvalue of 1; b) a 
minimum factor loading of 0.45 and above; c) a minimum 
factorial complexity (multiple loading); d) a meaningful 
interpretation of the factor, and e) a percentage of ex-
tracted variance (5%) to determine the number of factors. 
A screen test between factors was plotted to consolidate 
the total number of factors to be extracted in factor anal-
ysis. The screen test based on the cut-off eigenvalues fur-
ther guided toward the number of factors to be retained 
for further analysis.
Ethical approval
The research project was carried out in accordance with 
the latest version of the Declaration of Helsinki and ap-
proved by Unifesp’s ethics committee (Ref.: CEP n. 464/99). 
All participants and their guardians gave informed writ-
ten consent before participating.
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results
Problem severity index
The mean score of PESQ problem severity index was 26.48 
(SD 9.3) among the non-clinical population and 42.89 (SD 
10.0) among the clinical population (p<0.001). This index 
was highly correlated with scores obtained by these popu-
lations on the DUSI-R (1.9±2.5 for the non-clinical sample 
and 6.7±2.8 for the clinical sample, p<.001) (Spearman 
coefficient: 0.83, p<0.001).
Cronbach’s alpha of the problem severity index was 
of 0.91, comparable to scores obtained in other PESQ 
studies.23,25 An evaluation of the load of each item on the 
alpha result was performed and all items contributed in 
an important way to this value.
After factor analysis of this 18-item index, a four-
factor solution was reached. These four factors captured 
68.70% of the unrotated and rotated variances. The four 
factors extracted were as follows: i) factor I – items 1 to 6 
(eingenvalue: 7.68); ii) factor II – items 8 and 10 to 14 
(eingenvalue: 1.91); iii) factor III – items 7 and 17 to 20 
(eingenvalue: 1.52); and iv) factor IV – item 16 (eingen-
value: 1.24). Data on factor loading and on variance are 
on Tables 2 and 3. Factors I, II and III present good inter-
nal consistency (Cronbach’s alpha of 0.870, 0.798 and 
0.852, respectively). Internal consistency of factor IV could 
not be calculated, as it is comprised of just one question. 
TABLE 2 Factor loading from the Varimax rotated factor 
structure matrix for the PESQ: Principal component 
extraction with Varimax rotation and Kaiser normalization.




















The mean score on the defensiveness index was 6.6±0.9 
among the non-clinical sample and 7.27±1.26 among the 
clinical sample (p=0.007). This suggests that both study 
groups did not provide compromised self-report data. The 
mean scores on the infrequency index were 0.1±0.4 and 
1.6±1.9, respectively (p<.001). Although there was a sig-
nificant difference between groups, both had very low 
mean scores on this scale and thus we can assume that, in 
general, adolescents did not show a tendency to fake bad 
behavior. The mean scores on the psychological indicators 
index were 2.0±1.6 and 2.7±2.2, respectively (p>.05). 
discussion
The data analysis provides support for the reliability and 
validity of the PESQ in a Brazilian youth population (15 
to 18 years old). It appears to be an efficient instrument 
for screening substance-related disorders among adoles-
cents. Statistically significant differences between the 
clinical and non-clinical samples were found on the Prob-
lem Severity Index. No cut-off was studied, but the high-
er the score, the higher the need of a detailed clinical 
evaluation. It is important to emphasize that PESQ eval-
uates not only parameters related to substance use but 
also considers individual and environmental character-
istics. This enriches the comprehension of the dependence 
phenomenon and contributes to a more detailed psychi-
atric diagnosis. 
Principal component factor analysis of the Brazilian 
version of PESQ resulted in a four-factor solution. In the 
validation of the original version of the instrument, only 
one factor was identified (eigenvalue of 6.8; percent of 
variance 38.1). Item factor loadings ranged from .50 to 
.74 (median .62). Separate principal component factor 
analyses were also computed by gender, and similar results 
were found. It is a concern that only one item loads on 
the fourth factor, as there was no covariance to consider 
except the item’s own variance. Different rotation meth-
ods were used in order to confirm this finding, always 
yielding the same results. The item (question 16) could 
not be excluded, as it was important for the whole scale 
internal consistency. 
This is of great interest, since the PESQ could be used 
as a large-scale screening instrument. Recently, the World 
Health Organization (WHO) has focused great attention 
on integrating mental disorders into primary care.27 This 
is especially important among low and middle-income 
countries (LAMIC), like Brazil. It is well-known that mil-
lions of people suffer from mental disorders, including 
substance abuse and dependence, and this leads to a great 
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social burden.20,27 Training primary care professionals for 
early identification of individuals at-risk is one of the 
most cost-effective interventions available.28 This is also 
the best way to reduce the gap on mental health facili-
ties,20,28 present in many LAMIC, including Brazil. Having 
a short, cheap and effective instrument such as PESQ 
available for the Brazilian context is very useful. It could 
be widely used in schools or in primary care facilities by 
any health professional. 
Some limitations of this study must also be consid-
ered. First, a high alpha value does not necessarily estab-
lish good internal consistency. As the alpha is affected by 
the length of the test, adding related items testing the 
same concept increases its value.19 This probably is not 
the case here, because in the problem severity index we 
are dealing with an 18-item scale, not a long one. Moreover, 
sample size and gender difference between both samples 
may have biased our findings. Factor analysis is very sen-
sitive to the size of correlation, and correlation coefficients 
tend to be less reliable when estimated from small sample 
sizes.18 However, the high load of each factor obtained 
and the small number of factors found probably assure 
that this was not a problem, either.6 Finally, additional 
validity data are needed regarding how well the Brazilian 
PESQ predicts a criterion variable (e.g., substance use 
disorder diagnosis).
resuMo
Propriedades psicométricas da versão brasileira do Per-
sonal Experience Screening Questionnaire
Introdução: o Personal Experience Screening Question-
naire (PESQ) é um instrumento destinado ao rastreamen-
to de problemas relacionados ao uso de drogas entre 
adolescentes. Entretanto, suas propriedades psicométri-
cas não foram avaliadas em populações de adolescentes 
de outros países além dos Estados Unidos. 
Objetivo: avaliar a confiabilidade e a validade da versão 
brasileira do PESQ. 
Método: foi feito um estudo transversal envolvendo 84 
adolescentes de uma amostra clínica e de uma amostra 
não clínica. Todos responderam ao PESQ. 
Resultados: entre os adolescentes da população geral, o 
índice de severidade de problema da PESQ, que pode 
variar de 18 a 72, foi de 26,48±9,28. Por outro lado, a 
população clínica teve pontuação de 42,89±10,02 (p<0,001). 
O alfa de Cronbach foi de 0,91. A análise fatorial resultou 
em uma solução de quatro fatores. Além disso, ambas as 
populações apresentaram pontuações significativamente 
diferentes em outras subescalas do PESQ. 
Conclusão: as evidências sustentam a validade e a con-
fiabilidade da versão brasileira do PESQ. 
TABLE 3 Total variance explained (extraction method): Principal component analysis.
Component Initial eigenvalues Extraction sums of squared loadings Rotation sums of squared loadings
Total % of variance Cumulative % Total % of variance Cumulative % Total % of variance Cumulative %
1 7.688 42.710 42.710 7.688 42.710 42.710 4.178 23.209 23.209
2 1.916 10.642 53.352 1.916 10.642 53.352 3.258 18.099 41.308
3 1.518 8.435 61.787 1.518 8.435 61.787 2.872 15.958 57.266
4 1.246 6.921 68.707 1.246 6.921 68.707 2.059 11.441 68.707
5 0.852 4.736 73.443
6 0.741 4.116 77.559
7 0.645 3.586 81.145
8 0.624 3.464 84.609
9 0.475 2.638 87.247
10 0.463 2.571 89.818
11 0.355 1.972 91.790
12 0.332 1.845 93.635
13 0.297 1.648 95.283
14 0.249 1.385 96.668
15 0.195 1.081 97.749
16 0.177 0.983 98.732
17 0.142 0.787 99.519
18 0.087 0.481 100.000
Extraction method: Principal component analysis.
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Palavras-chave: drogas, rastreamento, escala, validação, 
confiabilidade.
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